Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
SF3B1 mutation
i
Other names:
SF3B1, Splicing Factor 3b Subunit 1, Splicing Factor 3b Subunit 1 155kDa, Spliceosome-Associated Protein 155, Splicing Factor 3B Subunit 1, SF3b155, SAP155, Pre-MRNA Splicing Factor SF3b 155 KDa Subunit, Pre-MRNA-Splicing Factor SF3b 155 KDa Subunit, Splicing Factor 3b Subunit 1 155kD, Pre-MRNA Processing 10, SAP 155, Hsh155, PRPF10, PRP10, MDS
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
23451
Related biomarkers:
Mutation
Others
‹
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
SF3B1 mutation
Myelodysplastic Syndrome
SF3B1 mutation
Myelodysplastic Syndrome
luspatercept-aamt
Sensitive: A2 - Guideline
luspatercept-aamt
Sensitive
:
A2
luspatercept-aamt
Sensitive: A2 - Guideline
luspatercept-aamt
Sensitive
:
A2
SF3B1 mutation
Chronic Lymphocytic Leukemia
SF3B1 mutation
Chronic Lymphocytic Leukemia
ofatumumab
Resistant: B - Late Trials
ofatumumab
Resistant
:
B
ofatumumab
Resistant: B - Late Trials
ofatumumab
Resistant
:
B
SF3B1 mutation
Chronic Lymphocytic Leukemia
SF3B1 mutation
Chronic Lymphocytic Leukemia
chlorambucil
Resistant: B - Late Trials
chlorambucil
Resistant
:
B
chlorambucil
Resistant: B - Late Trials
chlorambucil
Resistant
:
B
SF3B1 mutation
Chronic Lymphocytic Leukemia
SF3B1 mutation
Chronic Lymphocytic Leukemia
obinutuzumab
Resistant: B - Late Trials
obinutuzumab
Resistant
:
B
obinutuzumab
Resistant: B - Late Trials
obinutuzumab
Resistant
:
B
SF3B1 mutation
Chronic Lymphocytic Leukemia
SF3B1 mutation
Chronic Lymphocytic Leukemia
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
SF3B1 mutation
Acute Myelogenous Leukemia
SF3B1 mutation
Acute Myelogenous Leukemia
CA-4948
Sensitive: C2 – Inclusion Criteria
CA-4948
Sensitive
:
C2
CA-4948
Sensitive: C2 – Inclusion Criteria
CA-4948
Sensitive
:
C2
SF3B1 mutation
Myelodysplastic Syndrome
SF3B1 mutation
Myelodysplastic Syndrome
CA-4948
Sensitive: C2 – Inclusion Criteria
CA-4948
Sensitive
:
C2
CA-4948
Sensitive: C2 – Inclusion Criteria
CA-4948
Sensitive
:
C2
SF3B1 mutation
Acute Myelogenous Leukemia
SF3B1 mutation
Acute Myelogenous Leukemia
cytarabine/daunorubicin liposomal formulation
Sensitive: C3 – Early Trials
cytarabine / daunorubicin liposomal formulation
Sensitive
:
C3
cytarabine/daunorubicin liposomal formulation
Sensitive: C3 – Early Trials
cytarabine / daunorubicin liposomal formulation
Sensitive
:
C3
SF3B1 mutation
Acute Myelogenous Leukemia
SF3B1 mutation
Acute Myelogenous Leukemia
venetoclax
Resistant: C3 – Early Trials
venetoclax
Resistant
:
C3
venetoclax
Resistant: C3 – Early Trials
venetoclax
Resistant
:
C3
SF3B1 mutation
Myelodysplastic Syndrome
SF3B1 mutation
Myelodysplastic Syndrome
lenalidomide
Resistant: C3 – Early Trials
lenalidomide
Resistant
:
C3
lenalidomide
Resistant: C3 – Early Trials
lenalidomide
Resistant
:
C3
SF3B1 mutation
Acute Myelogenous Leukemia
SF3B1 mutation
Acute Myelogenous Leukemia
venetoclax + ABBV 075
Sensitive: C3 – Early Trials
venetoclax + ABBV 075
Sensitive
:
C3
venetoclax + ABBV 075
Sensitive: C3 – Early Trials
venetoclax + ABBV 075
Sensitive
:
C3
SF3B1 mutation
Chronic Lymphocytic Leukemia
SF3B1 mutation
Chronic Lymphocytic Leukemia
obinutuzumab + GS-9973
Sensitive: C3 – Early Trials
obinutuzumab + GS-9973
Sensitive
:
C3
obinutuzumab + GS-9973
Sensitive: C3 – Early Trials
obinutuzumab + GS-9973
Sensitive
:
C3
SF3B1 mutation
Chronic Lymphocytic Leukemia
SF3B1 mutation
Chronic Lymphocytic Leukemia
venetoclax
Resistant: C3 – Early Trials
venetoclax
Resistant
:
C3
venetoclax
Resistant: C3 – Early Trials
venetoclax
Resistant
:
C3
SF3B1 mutation
Chronic Lymphocytic Leukemia
SF3B1 mutation
Chronic Lymphocytic Leukemia
RG7388
Resistant: C3 – Early Trials
RG7388
Resistant
:
C3
RG7388
Resistant: C3 – Early Trials
RG7388
Resistant
:
C3
SF3B1 mutation
Chronic Myeloid Leukemia
SF3B1 mutation
Chronic Myeloid Leukemia
VE-821
Sensitive: D – Preclinical
VE-821
Sensitive
:
D
VE-821
Sensitive: D – Preclinical
VE-821
Sensitive
:
D
SF3B1 mutation
Melanoma
SF3B1 mutation
Melanoma
Immunotherapy
Sensitive: D – Preclinical
Immunotherapy
Sensitive
:
D
Immunotherapy
Sensitive: D – Preclinical
Immunotherapy
Sensitive
:
D
SF3B1 mutation
Acute Myelogenous Leukemia
SF3B1 mutation
Acute Myelogenous Leukemia
HPB-092
Sensitive: D – Preclinical
HPB-092
Sensitive
:
D
HPB-092
Sensitive: D – Preclinical
HPB-092
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login